Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma. Cancer Chemother Pharmacol. 2008 Apr; 61(4):549-58.
View in:
PubMed
subject areas
Antineoplastic Agents
Antineoplastic Combined Chemotherapy Protocols
Apoptosis
Boronic Acids
Bortezomib
Cell Cycle
Cell Line, Tumor
Cell Survival
Cisplatin
Drug Evaluation, Preclinical
Drug Resistance, Multiple
Drug Resistance, Neoplasm
Flow Cytometry
Genes, Intracisternal A-Particle
Glutamates
Guanine
Humans
Mesothelioma
Neoplasm Proteins
Pemetrexed
Pleural Neoplasms
Proteasome Inhibitors
Pyrazines
Survival Analysis
authors with profiles
Ravi Salgia
Hedy Kindler